Table Legends:
Table I: Baseline characteristics of Cohort 1. a) Patients with melanoma and combination ipilimumab and nivolumab-associated colitis (IN-COL) or treated patients with no adverse side-effects (IN-NAE). b) Patients with ulcerative colitis (UC). Comparisons made by Mann-Whitney test and Chi-squared test for continuous and categorical data, respectively. AJCCv8=American joint committee of cancer melanoma staging system 8th edition; N/A= not applicable.
Table II: Baseline characteristics of Cohort 2. Comparisons made by Mann-Whitney test and Chi-squared test for continuous and categorical data, respectively. *p<0.05 compared to Cohort 1 IN-NAE. AJCCv8=American joint committee of cancer melanoma staging system 8th edition; N/A= not available.
Table III: Baseline characteristics of Cohort 3 a) Patients with melanoma with combination ipilimumab and nivolumab-associated colitis (IN-COL) or treated patients with no adverse side-effects (IN-NAE). b) Healthy volunteers and patients with ulcerative colitis (UC). c) Comparison of UC and IN-COL clinical, endoscopic and histopathological features.
Supplementary Table I: Characterisation of the peripheral blood mononuclear cell (PBMC) compartment in patients with combination ipilimumab and nivolumab-associated colitis. *p<0.05 **p<0.01 ***p<0.001 compared with healthy volunteers; †p<0.05 ††p<0.01 for combination ipilimumab and nivolumab-associated colitis (IN-COL) compared to baseline; ¶p<0.05 ¶¶<0.01 for combination ipilimumab and nivolumab-treated patients with nil adverse events (IN-NAE) compared to baseline. All refer to Mann-Whitney tests with no correction.